Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 7,081 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Not applicable Interventional

Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy

NCT01941784
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
educational intervention, counseling intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment
Other · Behavioral · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 3 Interventional Results available

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744
View directory record Official record
Conditions
Metastasis, Breast Cancer
Interventions
NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Nov 3, 2026, 5:41 AM EST
Recruiting Phase 2 Interventional

ATEMPT 2.0: Adjuvant T-DM1 vs TH

NCT04893109
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
trastuzumab-emtansine, Trastuzumab SC, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
53
States / cities
San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Terminated Early Phase 1 Interventional Results available

FPA150 in Patients With Advanced Solid Tumors

NCT03514121
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
Interventions
FPA150, Pembrolizumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 1 Interventional

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

NCT02650752
View directory record Official record
Conditions
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Interventions
Lapatinib in Tandem With Capecitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Ann Arbor, Michigan • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Nov 3, 2026, 5:41 AM EST
Completed Not applicable Interventional

Pain Management Following TRAM Flap for Breast Reconstruction

NCT00500565
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, Bupivicaine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Nov 3, 2026, 5:41 AM EST
Completed No phase listed Observational

Development of a Patient Decision Aid for Women Considering Breast Reconstruction

NCT04817709
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Educational Intervention, Usual Care, Media Intervention, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 2 Interventional Results available

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

NCT03121352
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Carboplatin, Nab-paclitaxel, Pembrolizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 3, 2026, 5:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Intraoperative Pathway in DIEP Flap Breast Reconstruction

NCT00543764
View directory record Official record
Conditions
Breast Cancer
Interventions
pathway
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 1Phase 2 Interventional Results available

Partial Breast Irradiation With Chemotherapy

NCT00278109
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Doxorubicin, radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 3, 2026, 5:41 AM EST
Not yet recruiting Not applicable Interventional

Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits

NCT07799467
View directory record Official record
Conditions
Breast Cancer, Alcohol Drinking
Interventions
Sobriety Digital Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
40 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Nov 3, 2026, 5:41 AM EST
Recruiting Phase 1 Interventional

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

NCT06150664
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions
CTX-8371
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Margate, Florida • Orlando, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Completed No phase listed Observational

Morphine for the Treatment of Pain in Patients With Breast Cancer

NCT00003000
View directory record Official record
Conditions
Pain
Interventions
fentanyl citrate, morphine sulfate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 3, 2026, 5:41 AM EST
Not listed Not applicable Interventional

Enhancing Hope Among Patients With Poor-Prognosis Breast Cancer and Oncologists

NCT03074071
View directory record Official record
Conditions
Despair Among Cancer Patients and Oncologists
Interventions
Hope Enhancement Workshop
Behavioral
Lead sponsor
Tel-Aviv Sourasky Medical Center
Government
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 1 Interventional Results available

Vaccination of High Risk Breast Cancer Patients

NCT01390064
View directory record Official record
Conditions
Stage IV Breast Cancer
Interventions
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Nov 3, 2026, 5:41 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plant-based Diets and Risk of Cancer in the Adventist Health Study-2

NCT03615599
View directory record Official record
Conditions
Cancer, Breast, Cancer, Colorectal, Cancer, Prostate
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
30 Years and older
Enrollment
96,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 2 Interventional Results available

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

NCT00894504
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Panitumumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
17
States / cities
Thousand Oaks, California • Aventura, Florida • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Nov 3, 2026, 5:41 AM EST
Recruiting Phase 3 Interventional

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767
View directory record Official record
Conditions
Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
62
States / cities
Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Active, not recruiting Not applicable Interventional

Partial Breast Proton Therapy for Early Stage Breast Cancer

NCT01310530
View directory record Official record
Conditions
Breast Cancer
Interventions
Proton Beam Radiotherapy
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 3, 2026, 5:41 AM EST
Completed Phase 2 Interventional Results available

Ixabepilone + Carboplatin Metastatic Breast Cancer

NCT01075100
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone, Carboplatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
59
States / cities
Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Nov 3, 2026, 5:41 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo

NCT01934114
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
25 Years to 76 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Nov 3, 2026, 5:41 AM EST